Shearman & Sterling advised the underwriters of Nkarta, Inc.’s initial public offering of 16,100,000 shares of common stock, including the underwriters’ full exercise of their over-allotment option to purchase up to 2,100,000 additional shares, at a public offering price of $18.00 per share, resulting in gross proceeds to Nkarta of approximately $289.8 million. The shares began trading on the Nasdaq Global Select Market under the ticker symbol “NKTX” on July 10, 2020. 

Cowen, Evercore ISI, Stifel and Mizuho Securities acted as joint book-running managers for the offering.

Nkarta, Inc. is a clinical stage biopharmaceutical company focused on combining its natural killer (NK) cell expansion and cryopreservation platform with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer.

The Team